[{"id":"8d686149-a583-41f2-8927-e211fb3a2fb7","acronym":"QTX3034-001","url":"https://clinicaltrials.gov/study/NCT06227377","created_at":"2024-01-26T18:20:28.721Z","updated_at":"2024-07-02T16:35:00.369Z","phase":"Phase 1","brief_title":"QTX3034 in Patients With KRAS G12D Mutation","source_id_and_acronym":"NCT06227377 - QTX3034-001","lead_sponsor":"Quanta Therapeutics","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • QTX3034"],"overall_status":"Recruiting","enrollment":" Enrollment 250","initiation":"Initiation: 02/05/2024","start_date":" 02/05/2024","primary_txt":" Primary completion: 04/01/2027","primary_completion_date":" 04/01/2027","study_txt":" Completion: 04/01/2027","study_completion_date":" 04/01/2027","last_update_posted":"2024-05-29"}]